Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials-Reference-Cited by-同舟云学术

Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials

Published:2020-02-27 Issue:4 Volume:37 Page:1496-1521
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Mu Guangyan,Xiang Qian,Zhou Shuang,Liu Zhiyan,Qi Litong,Jiang Jie,Gong Yanjun,Xie Qiufen,Wang Zining,Zhang Hanxu,Huo Yong,Cui Yimin

Funder

National Science and Technology Major Projects for “Major New Drugs Innovation and Development”

Science and Technology Service Network Plan

Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos

National Key R&D Program of China

National Natural Science Foundation of China

Natural Science Foundation of Beijing Municipality

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-020-01259-4.pdf

Reference63 articles.

1. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.

2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285–350.

3. Mach F, Baigent C, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;2019:1–78.

4. Kinoshita M, Yokote K, Arai H, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25:846–984.

5. Zhang X-L, Zhu Q-Q, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Targeting of Pattern Recognition Receptors to Modulate Inflammation in Atherosclerosis;Cell Biochemistry and Biophysics;2024-08-15

2. ASGR1 is a promising target for lipid reduction in pigs with PON2 as its inhibitor;iScience;2024-07

3. PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes;Cardiovascular Drugs and Therapy;2024-06-22

4. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial;Cardiovascular Research;2024-05-16

5. Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review);International Journal of Molecular Medicine;2024-05-10